Murray Stewart - 01 Jan 2026 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Director
Issuer ticker: XFOR
Reported as of: 01 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jan 2026, 16:04:43 UTC
Prior SEC filing: 10 Jun 2025
Next SEC filing: 12 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ David Kirske, attorney-in-fact

Key filing fact

Murray Stewart filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 05 Jan 2026.

Key facts

This page summarizes Murray Stewart's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2026, 16:04.

Change

Previous filing in this sequence was filed on 10 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001723450 Primary reporting owner

Stewart Murray

Relationship: Director
Address: C/O X4 PHARMACEUTICALS, INC., 61 NORTH BEACON STREET, 4TH FLOOR, BOSTON
Signature: /s/ David Kirske, attorney-in-fact
Signature date: 05 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XFOR transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +110,000
Change %
Price: $0.000000
Shares after: 0
Date: 01 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 110,000
Exercise price: $4.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.

SEC remarks

Exhibit List: Exhibit 24 Power of Attorney